In vivo role of heme oxygenase in ischemic coronary vasodilation

Yasuhiro Nishikawa, David W Stepp, Daphne Merkus, Deron Jones, William M. Chilian

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The heart constitutively expresses heme oxygenase (HO)-2, which catabolizes heme-containing proteins to produce biliverdin and carbon monoxide (CO). The heart also contains many possible substrates for HO-2 such as heme groups of myoglobin and cytochrome P-450s, which potentially could be metabolized into CO. As a result of observations that CO activates guanylyl cyclase and induces vascular relaxation and that HO appears to confer protection from ischemic injury, we hypothesized that the HO-CO pathway is involved in ischemic vasodilation in the coronary microcirculation. Responses of epicardial coronary arterioles to ischemia (perfusion pressure ∼40 mmHg; flow velocity decreased by ∼50%; dL/dt reduced by ∼60%) were measured using stroboscopic fluorescence microangiography in 34 open-chest anesthetized dogs. Ischemia caused vasodilation of coronary arterioles by 36 ± 6%. Administration of NG-monomethyl-L-arginine (L-NMMA, 3 μmol·kg-1·min-1 intracoronary), indomethacin (10 mg/kg iv), and K+ (60 mM, epicardial suffusion) to prevent the actions of nitric oxide, prostaglandins, and hyperpolarizing factors, respectively, partially inhibited dilation during ischemia (36 ± 6 vs. 15 ± 4%; P < 0.05). The residual vasodilation during ischemia after antagonist administration was inhibited by tin mesoporphyrin IX (SnMP, 10 mg/kg iv), which is an inhibitor of HO (15 ± 4 vs. 7 ± 2%; P < 0.05 vs. before SnMP). The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10-5 M, epicardial suffusion) also inhibited vasodilation during ischemia in the presence of L-NMMA with indomethacin and KCl. Moreover, administration of heme-L-arginate, which is a substrate for HO, produced dilation after ischemia but not after control conditions. We conclude that during myocardial ischemia, HO-2 activation can produce cGMP-mediated vasodilation presumably via the production of CO. This vasodilatory pathway appears to play a backup role and is activated only when other mechanisms of vasodilation during ischemia are exhausted.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume286
Issue number6 55-6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Heme Oxygenase (Decyclizing)
Vasodilation
Ischemia
Carbon Monoxide
omega-N-Methylarginine
Guanylate Cyclase
Arterioles
Heme
Indomethacin
Dilatation
Biliverdine
Oxadiazoles
Quinoxalines
Myoglobin
Cytochromes
Microcirculation
Prostaglandins
Myocardial Ischemia
Blood Vessels
Nitric Oxide

Keywords

  • Carbon monoxide
  • Hypoperfusion
  • Ischemia
  • Microcirculation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

In vivo role of heme oxygenase in ischemic coronary vasodilation. / Nishikawa, Yasuhiro; Stepp, David W; Merkus, Daphne; Jones, Deron; Chilian, William M.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 286, No. 6 55-6, 01.06.2004.

Research output: Contribution to journalArticle

Nishikawa, Yasuhiro ; Stepp, David W ; Merkus, Daphne ; Jones, Deron ; Chilian, William M. / In vivo role of heme oxygenase in ischemic coronary vasodilation. In: American Journal of Physiology - Heart and Circulatory Physiology. 2004 ; Vol. 286, No. 6 55-6.
@article{8e76beb09f274823962c6f7ce7213f83,
title = "In vivo role of heme oxygenase in ischemic coronary vasodilation",
abstract = "The heart constitutively expresses heme oxygenase (HO)-2, which catabolizes heme-containing proteins to produce biliverdin and carbon monoxide (CO). The heart also contains many possible substrates for HO-2 such as heme groups of myoglobin and cytochrome P-450s, which potentially could be metabolized into CO. As a result of observations that CO activates guanylyl cyclase and induces vascular relaxation and that HO appears to confer protection from ischemic injury, we hypothesized that the HO-CO pathway is involved in ischemic vasodilation in the coronary microcirculation. Responses of epicardial coronary arterioles to ischemia (perfusion pressure ∼40 mmHg; flow velocity decreased by ∼50{\%}; dL/dt reduced by ∼60{\%}) were measured using stroboscopic fluorescence microangiography in 34 open-chest anesthetized dogs. Ischemia caused vasodilation of coronary arterioles by 36 ± 6{\%}. Administration of NG-monomethyl-L-arginine (L-NMMA, 3 μmol·kg-1·min-1 intracoronary), indomethacin (10 mg/kg iv), and K+ (60 mM, epicardial suffusion) to prevent the actions of nitric oxide, prostaglandins, and hyperpolarizing factors, respectively, partially inhibited dilation during ischemia (36 ± 6 vs. 15 ± 4{\%}; P < 0.05). The residual vasodilation during ischemia after antagonist administration was inhibited by tin mesoporphyrin IX (SnMP, 10 mg/kg iv), which is an inhibitor of HO (15 ± 4 vs. 7 ± 2{\%}; P < 0.05 vs. before SnMP). The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10-5 M, epicardial suffusion) also inhibited vasodilation during ischemia in the presence of L-NMMA with indomethacin and KCl. Moreover, administration of heme-L-arginate, which is a substrate for HO, produced dilation after ischemia but not after control conditions. We conclude that during myocardial ischemia, HO-2 activation can produce cGMP-mediated vasodilation presumably via the production of CO. This vasodilatory pathway appears to play a backup role and is activated only when other mechanisms of vasodilation during ischemia are exhausted.",
keywords = "Carbon monoxide, Hypoperfusion, Ischemia, Microcirculation",
author = "Yasuhiro Nishikawa and Stepp, {David W} and Daphne Merkus and Deron Jones and Chilian, {William M.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1152/ajpheart.00671.2003",
language = "English (US)",
volume = "286",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "6 55-6",

}

TY - JOUR

T1 - In vivo role of heme oxygenase in ischemic coronary vasodilation

AU - Nishikawa, Yasuhiro

AU - Stepp, David W

AU - Merkus, Daphne

AU - Jones, Deron

AU - Chilian, William M.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - The heart constitutively expresses heme oxygenase (HO)-2, which catabolizes heme-containing proteins to produce biliverdin and carbon monoxide (CO). The heart also contains many possible substrates for HO-2 such as heme groups of myoglobin and cytochrome P-450s, which potentially could be metabolized into CO. As a result of observations that CO activates guanylyl cyclase and induces vascular relaxation and that HO appears to confer protection from ischemic injury, we hypothesized that the HO-CO pathway is involved in ischemic vasodilation in the coronary microcirculation. Responses of epicardial coronary arterioles to ischemia (perfusion pressure ∼40 mmHg; flow velocity decreased by ∼50%; dL/dt reduced by ∼60%) were measured using stroboscopic fluorescence microangiography in 34 open-chest anesthetized dogs. Ischemia caused vasodilation of coronary arterioles by 36 ± 6%. Administration of NG-monomethyl-L-arginine (L-NMMA, 3 μmol·kg-1·min-1 intracoronary), indomethacin (10 mg/kg iv), and K+ (60 mM, epicardial suffusion) to prevent the actions of nitric oxide, prostaglandins, and hyperpolarizing factors, respectively, partially inhibited dilation during ischemia (36 ± 6 vs. 15 ± 4%; P < 0.05). The residual vasodilation during ischemia after antagonist administration was inhibited by tin mesoporphyrin IX (SnMP, 10 mg/kg iv), which is an inhibitor of HO (15 ± 4 vs. 7 ± 2%; P < 0.05 vs. before SnMP). The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10-5 M, epicardial suffusion) also inhibited vasodilation during ischemia in the presence of L-NMMA with indomethacin and KCl. Moreover, administration of heme-L-arginate, which is a substrate for HO, produced dilation after ischemia but not after control conditions. We conclude that during myocardial ischemia, HO-2 activation can produce cGMP-mediated vasodilation presumably via the production of CO. This vasodilatory pathway appears to play a backup role and is activated only when other mechanisms of vasodilation during ischemia are exhausted.

AB - The heart constitutively expresses heme oxygenase (HO)-2, which catabolizes heme-containing proteins to produce biliverdin and carbon monoxide (CO). The heart also contains many possible substrates for HO-2 such as heme groups of myoglobin and cytochrome P-450s, which potentially could be metabolized into CO. As a result of observations that CO activates guanylyl cyclase and induces vascular relaxation and that HO appears to confer protection from ischemic injury, we hypothesized that the HO-CO pathway is involved in ischemic vasodilation in the coronary microcirculation. Responses of epicardial coronary arterioles to ischemia (perfusion pressure ∼40 mmHg; flow velocity decreased by ∼50%; dL/dt reduced by ∼60%) were measured using stroboscopic fluorescence microangiography in 34 open-chest anesthetized dogs. Ischemia caused vasodilation of coronary arterioles by 36 ± 6%. Administration of NG-monomethyl-L-arginine (L-NMMA, 3 μmol·kg-1·min-1 intracoronary), indomethacin (10 mg/kg iv), and K+ (60 mM, epicardial suffusion) to prevent the actions of nitric oxide, prostaglandins, and hyperpolarizing factors, respectively, partially inhibited dilation during ischemia (36 ± 6 vs. 15 ± 4%; P < 0.05). The residual vasodilation during ischemia after antagonist administration was inhibited by tin mesoporphyrin IX (SnMP, 10 mg/kg iv), which is an inhibitor of HO (15 ± 4 vs. 7 ± 2%; P < 0.05 vs. before SnMP). The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (10-5 M, epicardial suffusion) also inhibited vasodilation during ischemia in the presence of L-NMMA with indomethacin and KCl. Moreover, administration of heme-L-arginate, which is a substrate for HO, produced dilation after ischemia but not after control conditions. We conclude that during myocardial ischemia, HO-2 activation can produce cGMP-mediated vasodilation presumably via the production of CO. This vasodilatory pathway appears to play a backup role and is activated only when other mechanisms of vasodilation during ischemia are exhausted.

KW - Carbon monoxide

KW - Hypoperfusion

KW - Ischemia

KW - Microcirculation

UR - http://www.scopus.com/inward/record.url?scp=2542497841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542497841&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00671.2003

DO - 10.1152/ajpheart.00671.2003

M3 - Article

C2 - 15148058

AN - SCOPUS:2542497841

VL - 286

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 6 55-6

ER -